Understand the source comparison
Thymalin vs KPV vs Epitalon: Immune Pathway Comparison
Thymalin Thymulin receptor agonist. Promotes T-cell maturation in thymic tissue Thymic epithelial cells, T-lymphocyte progenitors 5–10mg per injection 2–3 times weekly Phase 2 trials showing 34% naive T-cell increase over 8 weeks (Immunity & Ageing 2021) KPV α
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymulin receptor agonist. Promotes T-cell maturation in thymic tissue
- Thymic epithelial cells, T-lymphocyte progenitors
- 5–10mg per injection
- 2–3 times weekly
- Phase 2 trials showing 34% naive T-cell increase over 8 weeks (Immunity & Ageing 2021)
- KPV
- α-MSH derivative. Inhibits NF-kB inflammatory signaling
- Gut epithelial cells, macrophages
- 500–1000mcg per injection
- Daily during acute flares, 3x weekly maintenance
- Preclinical models showing 40–55% reduction in TNF-alpha and IL-6 (UC San Diego)
- Epitalon
- Telomerase activator. Indirect immune support through cellular senescence reduction
- All dividing cell types including lymphocytes
- 10-day cycles, 2–3 times yearly
- Observational studies showing extended lymphocyte lifespan, no RCTs published